TRiCaresAnnounced the completion of a new round of 50 million US dollars (46 million euros) financing, this round of financing was led by oneInvestment by undisclosed strategic investors.The proceeds from this round of financing will be mainly used to supportTopazInThe United States and the European Union conduct clinical research (including completing an Early Feasibility Study (EFS) in the United States and launching a pivotal trial in Europe), as well as forTopazSize optimization, and the development of the next-generation delivery system.
"I am delighted that we have secured this significant funding at such a crucial stage of our business. This financing builds on the previous investments from Europe's leading life science venture capital firms, and we appreciate their ongoing support and guidance. We remain committed to improving treatment options for patients with tricuspid regurgitation worldwide through our Topaz, and we look forward to providing the latest updates on U.S. patient enrollment alongside our efforts in Europe."---Ahmed Elmouelhi, President and CEO of TRiCaresIn the TTVR field, apart from TRiCaresHuá's EVOQUE has been approved by the FDA for marketing. Other participants are more or less at the same starting line, either in preclinical or clinical research. In this field, the gap between Chinese and overseas products is narrowing. China-produced LuX-Vavle has also received positive clinical feedback, but unfortunately, it was rejected by NMPA due to non-rigorous clinical research. It’s a pity that we won’t see its domestic launch this year.
TopazIt is an advanced TTVR product that has been successfully implanted in 25 cases in Europe and Canada. And it will beTo be launched in up to 8 centers across the United States and Canada in the coming months.Early Feasibility Study (EFS).
TopazIt is an innovative transcatheter tricuspid valve replacement device designed to help patients with severe tricuspid regurgitation without the need for cardiac surgery.TopazImplanted through the patient's femoral vein and specifically designed to fit the tricuspid valve anatomy, thus facilitating positioning and function.TopazLike all TTVR products, it consists of a valve prosthesis and a delivery system.Among whichThe valve prosthesis is composed ofComposed of external stent and internal stent- External stent, designed for in-situ fixation on native tricuspid valve leaflets, can effectively adapt to the varying shapes and sizes of patients' anatomical structures;
- The internal stent serves as the framework for the Tricares pericardial tissue valve, aiming to achieve proper valve function and long-term performance.Trileaflet Pericardial Tissue Valve isPorcine pericardium, sutured to the inner stent with more than 1000 stitches.The internal stent ensures the roundness of the valve (preventing deformation due to varying patient anatomy), allowing for optimal leaflet alignment.
TopazThe valve prosthesis adopts a secure fixation method without traumatic anchoring structures. It is also suitable for patients with annulus diameters up to 45mm, second generation.TopazValve prostheses can be applied toAnnulusPatients with 55mm。
TopazThe delivery system is a 29Fr delivery system with bidirectional bending adjustment functionality.
Topaz Demonstration
TRiCares
TRiCares Founded in 2013, TRiCares SAS is an innovative medical device company headquartered in Paris, France. Its vision is to bring a percutaneous tricuspid valve replacement system to market to help patients with severe tricuspid regurgitation avoid cardiac surgery.
